(19) World Intellectual Property Organization

International Bureau



(43) International Publication Date 11 November 2004 (11.11.2004)

(10) International Publication Number WO 2004/096818 A3

(51) International Patent Classification7: 9/6561, G01N 33/04

C07F 9/40.

(21) International Application Number:

PCT/EP2003/012423

(22) International Filing Date:

6 November 2003 (06.11.2003)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

PCT/US03/12901 25 April 2003 (25.04.2003) PCT/US03/12943 25 April 2003 (25.04.2003) US PCT/US03/12926 25 April 2003 (25.04.2003)

(71) Applicant (for all designated States except US): GILEAD SCHENCES, INC. [US/US], 333 Lakeside Drive, Foster City, CA 94404 (US).

(72) Inventors; and
(75) Inventors; and
(76) Inventors; and
(77) Inventors; and
(77) Inventors; and
(78) Inventors; and
(79) I

94024 (US). MCDERMOTT, Martin, J. [US/US]; 710 Bair Island Road, Suite 202, Redwood City, CA 94063 (US). SWAMINATHAN, Sundaramoorthi [IN/US]; 2858 Hillside Drive, Burlingame, CA 94010 (US).

- (74) Agents: RIEDL, Peter et al.; Reitstötter, Kinzebach & Partner (GbR), Sternwartstrasse 4, 81679 München (DE).
- (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU. CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW. MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (regional): ARIPO patent (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of
- (88) Date of publication of the international search report: 7 April 2005

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the begin-

Internal Application No PCT/EP 03/12423

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 C07F9/40 C07F9/6561 G01N33/04 According to International Petent Classification (IPC) or to both national classification and IPC B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) IPC 7 CO7F CO7H C12N C12Q Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched Electronic data base consulted during the International search (name of data base and, where practical, search terms used) EPO-Internal, BIOSIS C. DOCUMENTS CONSIDERED TO BE RELEVANT Citation of document, with indication, where appropriate, of the relevant passages Relevant to claim No. HAMMOND, J. L. ET AL.: "Alkylglycerol 1,7, Prodrugs of Phosphonoformate.... 14-17, 19,20, 27,38, ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, vol. 45, no. 6, June 2001 (2001-06), pages 1621-1628, XP002277443 42,43,62 page 1622; figure 1 HAKIMELAHI & H ET AL: "DESIGN, SYNTHESIS, X 1,7,8, AND STRUCTURE-ACTIVITY RELATIONSHIP OF 10, NOVEL DINUCLEOTIDE ANALOGS AS AGENTS 12 - 15.AGAINST HERPES AND HUMAN IMMUNODEFICIENCY 20,27, VIRUSES" 38,39, JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN 41,43, CHEMICAL SOCIETY. WASHINGTON, US 62,67 vol. 38, no. 23, 1995, pages 4648-4659, XP001145914 ISSN: 0022-2623 page 4648 - page 4652; table 4 -/--Further documents are listed in the continuation of box C. Patent family members are fisted in annex. Special categories of cited documents: *T* later document published after the International filing date or priority date and not in conflict with the application but dited to understand the principle or theory underlying the *A* document defining the general state of the art which is not considered to be of particular relevance invention *E* earlier document but published on or after the International *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone *L* document which may throw doubts on priority claim(e) or which is cited to establish the publication date of another challon or other special reason (as specified) "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such docu-ments, such combination being obvious to a person skilled in the art. "O" document referring to an oral disclosure, use, exhibition or other means document published prior to the international tiling date but later than the priority date claimed "&" document member of the same patent family Date of the actual complation of the international search Date of mailing of the international search report 11 02 2005 11 January 2005 Name and mailing address of the ISA Authorized officer European Patent Office, P.B. 5618 Patentlaan 2 NL - 2280 HV Pijswijk TE((+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016 Richter, H

Interpolation No PCT/EP 03/12423

(Continu	stion) DOCUMENTS CONSIDERED TO BE RELEVANT	
tegory °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
ζ.	KOFOED T ET AL: "REGIOISOMERS OF 2',3'-DIDEOXYNUCLEOSIDES RELATED TO 2-(PHOSPHONYLMETHOXY)ETHYL NUCLEOSIDES" BULLETIN DE LA SOCIETE CHIMIQUE DE FRANCE, SOCIETE FRANCAISE DE CHIMIE. PARIS, FR, vol. 134, 1997, pages 59-65, XP009004947 ISSN: 0037-8968 compounds 6a-6d, 7a-7e, 10a-10e, 11a-11e page 60, column 1, line 38 - page 61, column 2	1,7,10, 15,16, 20,27, 38,40, 43,62
	KRAUS J-L: "NEW PHOSPHONATE ANALOGUES OF 3'-THIA-2',3'-DIDEOXYCYTIDINE (BCH-189) SYNTHESIS AND ANTI-HIV EVALUATION" NUCLEOSIDES & NUCLEOTIDES, DEKKER, NEW YORK,NY,, US, vol. 12, no. 2, 1993, pages 157-162, XP009004946 ISSN: 0732-8311 scheme 1 page 157, line 22 - page 158	1,7,20, 27,38
	CHARVET ET AL: "Inhibition of Human Immunodefiency Virus Type 1 Replication by Phosphonoformate— and Phosphonoacetate— 2',3'—Dideoxy—3'—thiacytidine Conjugates" JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON, US, vol. 14, no. 37, 1994, pages 2216—2223, XP002072425 ISSN: 0022—2623 schemes 1—3: compounds 3,4,5—10, 12,13, 17,18; "Biological Results" table 1	1,7,20, 38-40, 42,43,62
	page 2219, column 2, paragraph 2	17,64,65
A	MENENDEZ-ARIAS L: "Targeting HIV: antiretroviral therapy and development of drug resistance" TRENDS IN PHARMACOLOGICAL SCIENCES, ELSEVIER, AMSTERDAM, NL, vol. 23, no. 8, 1 August 2002 (2002-08-01), pages 381-388, XP004386181 ISSN: 0165-6147 figure 1	1,7,8, 10, 12-15, 20,27, 38,39, 41,43, 62,67
	WO 01/39724 A (UNIV CALIFORNIA SAN DIEGO; KINI GANESH D (US); BEADLE JAMES R (US); H) 7 June 2001 (2001-06-07) page 3, line 4 - page 16, line 20; claims 1-6,13-15	1,7,8, 10,13, 20,27,38

ent tional Application No PCT/EP 03/12423

C-(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT				
Category •	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.		
Х	BALLATORE, C. ET AL.: "Synthesis and Evaluation of Novel Amidate Prodrugs of PMEA and PMPA" BIOORGANIC AND MEDICINAL CHEMISTRY LETTERS, vol. 11, no. 8, 23 April 2001 (2001-04-23), pages 1053-1056, XP0001180825 page 1054, column 2 - page 1055, column 2; figures 1,3,4; table 1	1,7,8, 10,12, 13,20, 27,38, 41,43, 62,67		
X	WO 01/96354 A (MARLIERE PHILIPPE; POCHET SYLVIE (FR); CENTRE NAT RECH SCIENT (FR); P) 20 December 2001 (2001-12-20) page 1, line 26 - page 7, line 11; claims 26,27	1,7,15, 16		
X	page 11, line 26 - page 12, line 4 page 12, line 5 - line 8; claims 21,28	17,20,27 38,40,43		
A	CLERCQ DE E: "NEW DEVELOPMENTS IN ANTI-HIV CHEMOTHERAPY" CURRENT MEDICINAL CHEMISTRY, BENTHAM SCIENCE PUBLISHERS BV, BE, vol. 8, no. 13, November 2001 (2001-11), pages 1543-1572, XP009012547 ISSN: 0929-8673 the whole document	1		
X .	WO 02/08241 A (GILEAD SCIENCES INC; BECKER MARK W (US); HE GONG XIN (US); LEE WILLIA) 31 January 2002 (2002-01-31)	1,7, 12-15, 17,20, 27, 38-41, 62, 67-70, 73,74, 76,78,		
X X	page 2 - page 16; claim 4; examples 1a,1b,2-7,9; table 7 page 11; claims 1,4-6,8 page 10, line 20 - line 24	82,86 71 72		
x	GORIN B I ET AL: "A Novel Esterification Procedure Applied to Synthesis of Biologically Active Esters of Foscarnet" TETRAHEDRON LETTERS, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, vol. 38, no. 16, 21 April 1997 (1997-04-21), pages 2791-2794, XP004058495 ISSN: 0040-4039 Scheme 1 page 2792; compound 1	38		
A	page 2793	43		

Internal Application No PCT/EP 03/12423

		PCT/EP 03/12423
Continu	ation) DOCUMENTS CONSIDERED TO BE RELEVANT Citation of document, with Indication, where appropriate, of the relevant passages	Relavant to claim No.
(WO 02/103008 A (GOUILAEV ALEX HAAHR; NOERREGAARD-MADSEN MADS (DK); SLOEK FRANK ABILGA) 27 December 2002 (2002-12-27)	38-41
	pages 104, 266,316, page 308 - page 309; examples 4,15,25,26,31,32	
	page 13, paragraph 1	43
X	DATABASE MEDLINE 'Online! US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US; May 2002 (2002-05), POKROVSKII A G ET AL: "Comparative analysis of HIV-1 resistance to AZT and AZT H-phosphonate in a cell culture." XP002296489 Database accession no. NLM12134511	1,18
	abstract & DOKLADY. BIOCHEMISTRY AND BIOPHYSICS. 2002 MAY-JUN, vol. 384, May 2002 (2002-05), pages 152-154, ISSN: 1607-6729 & DOKLADY AKADEMII NAUK, vol. 384, no. 2, May 2002 (2002-05), pages 259-262, ISSN: 0869-5652	
	DE CLERCQ E: "Chemotherapy of human immunodeficiency virus (HIV) infection: anti-HIV agents targeted at early stages in the virus replicative cycle" BIOMEDICINE AND PHARMACOTHERAPY, vol. 50, no. 5, 1996, pages 207-215, XP002296486 ISSN: 0753-3322 figure 13	2,5-7
Γ	US 2004/121316 A1 (CHEN XIAOWU ET AL) 24 June 2004 (2004-06-24)	1,23,24, 38-44, 46-61
	abstract	
(SAUBER K ET AL: "A new esterase for the cleavage of pivalic acid-containing prodrug esters of cephalosporins." ENZYME AND MICROBIAL TECHNOLOGY. JUL 1996, vol. 19, no. 1, July 1996 (1996-07), pages 15-19, XP002296487 ISSN: 0141-0229 page 15, column 1 - page 17, column 2; table 1	71
	-/	

intentional Application No PCT/EP 03/12423

	1017 E. 03/12423	3/12423		
C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT Category Catation of document, with indication, where appropriate, of the relevant passages Relevant to claim No.				
Citation of document, with Indication, where appropriate, of the relevant passages	Relevant to claim No.			
MENDES EDUARDA ET AL: "Synthesis, stability and in vitro dermal evaluation of aminocarbonyloxymethyl esters as prodrugs of carboxylic acid agents." BIOORGANIC & MEDICINAL CHEMISTRY. MAR 2002, vol. 10, no. 3, March 2002 (2002-03), pages 809-816, XP002296488 ISSN: 0968-0896 page 810 - page 815	71			
<u>.</u>	·			
·				
·				
·				
·				
		•		
	MENDES EDUARDA ET AL: "Synthesis, stability and in vitro dermal evaluation of aminocarbonyloxymethyl esters as prodrugs of carboxylic acid agents." BIOORGANIC & MEDICINAL CHEMISTRY. MAR 2002, vol. 10, no. 3, March 2002 (2002-03), pages 809-816, XP002296488 ISSN: 0968-0896	Chatton of document, with Indication, where appropriate, of the relevant passages MENDES EDUARDA ET AL: "Synthesis, stability and in vitro dermal evaluation of aminocarbonyloxymethyl esters as prodrugs of carboxylic acid agents." BIOORGANIC & MEDICINAL CHEMISTRY. MAR 2002, vol. 10, no. 3, March 2002 (2002-03), pages 809-816, XP002296488 ISSN: 0968-0896		



lemational application No. PCT/EP 03/12423

-	Box I	Observations where cortain claims were found unservabable (Continueties of these 4 of 5 and 1 and
_		Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)
	This into	ernational Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:
	1.	Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:
	2. X	Claims Nos.: 21,22,28, 29,30,45, 196-213, partially 1,8,13-17,20,23,27 because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful international Search can be carried out, specifically: see FURTHER INFORMATION sheet PCT/ISA/210
	3.	Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).
	Box II	Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)
_	This inte	ernational Searching Authority found multiple inventions in this international application, as follows:
	/ the	matoniai osai oling nautoris, iodito maiapie masmatanio in une imeritationiai approau ori, ao ioniosio.
		see additional sheet
	1. X	As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
	2.	As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
•	з. 🔲	As only some of the required additional search lees were limely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
	ı. 🔲	No required additional search fees were timely paid by the applicant. Consequently, this international Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:
1	temark (on Protest The additional search fees were accompanied by the applicant's protest. X No protest accompanied the payment of additional search fees.

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. claims: 8,13-17,20,27;69 partly: 1,7,10,12,38-44,62-68,70

Methods for identifying a compound and determining the anti-HIV activity of its phosphonate derivative. Means for the method.

2. claims: 3; partly: 1,19, 38-44

Methods for identifying a compound and determining the anti-HIV activity and tissue selectivity of its phosphonate derivative or metabolite. Means for the method.

3. claims: 4; partly: 1,19, 38-44

Methods for identifying a compound and determining the anti-HIV activity and intercellular residence time of its phosphonate derivative or metabolite. Means for the method.

4. claims: 6,36; partly: 2,5,7,10,11,12,25,26,31-34

Methods comprising selecting a non-nucleotide compound containing at least one esterified carboxyl group and determining the intracellular persistence of the compound or a esterolytic metabolite of the esterified carboxyl thereof

5. claims: 35,37; partly: 2,5,7,9 -12,25,26,31-34

Methods comprising selecting a non-nucleotide compound containing at least one esterified phosphonate group and determining the intracellular persistence of the compound or a esterolytic metabolite of the esterified phosphonate thereof

6. claims: 18; partly:1, 38-44

Methods for identifying a compound and determining the anti-HIV activity and the resistance of HIV to the phosphonate derivative of the compound or metabolite thereof. Means for the method.

7. claims: 46-61; partly: 1,23,24,38, 40-44

Methods for identifying a compound and determining the anti-HIV activity and susceptibility to hydrolysis of its carboxyl esters by GS-7340 Ester Hydrolase. Means for the method.

8. claims: partly: 38-44, 62-68,70

Method for identifying an ant —HIV compound and substituting it with an esterified carboxylate and assaying the product for its anti—HIV activity.

9. claims: 208,242,246; partly: 71-72, 210, 214, 218, 222, 234, 238-241, 243,244, 247-250

Prodrugs and method for identifying prodrugs involving the provision of a compound having an esterified phosphonate group and contacting the compound with an extract capable of catalysing the hydrolysis of a carboxylic ester.

10. claims: 245, 196; partly: 71-72, 210, 214, 218, 222, 234, 238-241,243, 244,-247-250

Prodrugs and method for identifying prodrugs involving the provision of a compound having an esterified carboxylate group and contacting the compound with an extract capable of catalysing the hydrolysis of a carboxylic ester.

11. claims: Partly 73-75,77-102

Prodrugs and method for identifying prodrugs involving the provision of a compound having an esterified phosphonate group and contacting the compound with an extract of peripheral blood having carboxylic ester hydrolase activity to produce a metabolite compoun

12. claims: 76, 200,204; Partly 73-75,77-102

Prodrugs and method for identifying prodrugs involving the provision of a compound having an esterified caboxylate group and contacting the compound with an extract of peripheral blood having carboxylic ester hydrolase activity to produce a metabolite compound. 76, 200,204

Partly 73-75,77-102,

13. claims: 103-134, 198, 201, 205, 206, 209,211, 212, 215, 216, 219, 220, 223, 224, 235, 236

Prodrugs and method for identifying prodrugs having an esterified phosphonate group involving the provision of a compound having an esterified phosphonate group and contacting the compound with GS-7340 Ester Hydrolase

14. claims: 135-165, 199, 203, 207, 213, 217, 221, 225, 237

Prodrugs and method for identifying prodrugs having an esterified carboxyl group involving the provision of a compound having an esterified carboxyl group and contacting the compound with GS-7340 Ester Hydrolase.

15. claims: partly: 166-168, 170-195

Method for identifying prodrugs having an esterified phosphonate group involving the provision of a compound having an esterified phosphonate group and contacting the compound with an extract of peripheral blood mononuclear cells.

16. claims: 169, partly: 166-168, 170-195

Method for identifying prodrugs having an esterified carboxyl group involving the provision of a compound having an esterified carboxyl group and contacting the compound with an extract of peripheral blood mononuclear cells.

17. claims: partly 1,23,24,38-44

Methods for identifying a compound and determining the anti-HIV activity and susceptibility to hydrolysis of its phosphonate esters by GS-7340 Ester Hydrolase. Means for the method.

Continuation of Box I.2

Claims Nos.: 21,22,28, 29,30,45, 196-213, partially 1,8,13-17,20,23,27

Claims 23 and 28 cannot be searched because the backreference is not clear; Art 6, PCT. Present claims 1,8,13-17,20,27 relate to an extremely large number of possible methods. Support within the meaning of Article 6 PCT and/or disclosure within the meaning of Article 5 PCT is to be found, however, for only a very small proportion of the methods claimed. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Consequently, the search has been carried out for those parts of the claims which relate to nucleoside derivatives and foscarnet derivatives.

At least one feature of claims 21,22,29,30,45 is directed to subject-matter of non-technical nature. Claims 29, 30, 45 inter alia include a method for doing business (Rule 39.1(iii) PCT)

Claims 196-213 cannot be searched because they belong to the group of "reach-through claims". Such claims lack clarity, support and sufficient disclosure according to the trilateral study project 3b- "Report on Comparative Study on Biotechnology Patent Practices".

The applicant's attention is drawn to the fact that claims relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure. If the application proceeds into the regional phase before the EPO, the applicant is reminded that a search may be carried out during examination before the EPO (see EPO Guideline C-VI, 8.5), should the problems which led to the Article 17(2) declaration be overcome.

INTERNATIONAL SEARCH REPORT Information on palent family members

PCT/EP 03/12423

Patent document Publication Patent family Publication cited in search report member(s) date WO 0139724 07-06-2001 A AU 1949701 A 12-06-2001 BR 0016058 A 15-07-2003 CA 2393410 A1 07-06-2001 CN 1414854 T 30-04-2003 EP 1233770 A2 28-08-2002 JP 2004500352 T 08-01-2004 WO 0139724 A2 07-06-2001 US 2004019232 A1 29-01-2004 US 2004127735 A1 01-07-2004 ZA 200204194 A 20-08-2003 WO 0196354 A 20-12-2001 FR 2810322 A1 21-12-2001 AU 6763801 A 24-12-2001 CA 2411036 A1 20-12-2001 EP 1290006 A1 12-03-2003 WO 0196354 A1 20-12-2001 JP 2004503559 T 05-02-2004 US 2004023240 A1 05-02-2004 WO 0208241 Α 31-01-2002 AU 8294101 A 05-02-2002 BG 107572 A 28-11-2003 BR 0112646 A 24-06-2003 CA 2416757 A1 31-01-2002 CN 1443189 T 17-09-2003 20030413 A3 CZ 17-12-2003 EE 20D300029 A 15-10-2004 EP 1301519 A2 16-04-2003 HU 29-09-2003 0301307 A2 JP 2004504402 T 12-02-2004 NO 20030270 A 20-03-2003 PL 360490 A1 06-09-2004 MO 0208241 A2 31-01-2002 US 2004018150 A1 29-01-2004 US 27-11-2003 2003219727 A1 US 2002119443 A1 29-08-2002 ZA 200210271 A 28-10-2003 WO 02103008 27-12-2002 CA 2451524 A1 27-12-2002 WO 02103008 A2 27-12-2002 WO 02102820 A1 27-12-2002 EP 1402024 A2 31-03-2004 ΕP 1401850 A1 31-03-2004 JP 2004535193 T 25-11-2004 US 2003143561 A1 31-07-2003 US 2004049008 A1 11-03-2004 WO 03078625 A2 25-09-2003 WO 03078445 A2 25-09-2003 WO 03078626 A2 25-09-2003 WO 03078050 A2 25-09-2003 WO 03078446 A2 25-09-2003 WO 03078627 A2 25-09-2003 EP 1487978 A2 22-12-2004 EP 1487848 A2 22-12-2004 EP 1487849 A2 22-12-2004 EP 1487850 A2 22-12-2004 EP 1487851 A2 22-12-2004 EP 1490384 A2 29-12-2004

Information on patent family members

In tional Application No PCT/EP 03/12423

Patent document cited in search report		Publication date		Patent family member(s)	Publication date
US 2004121316	A1	24-06-2004	MO MO	03090690 A2 03091264 A2 03090691 A2	06-11-2003 06-11-2003 06-11-2003

Form PCT/ISA/210 (patent family annex) (January 2004)